Seres Therapeutics Inc (MCRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.28-5.04%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Limit revenue decline to no worse than -57% next year: FY27 revenue est $0.3M vs FY26 $13.8M (-98%) vs -57% target.
Seres aims to fund operations through Q1 2027. It amended a key agreement with Nestlé. Analysts expect losses to shrink next year. The stock rose 18.8% in 21 days despite a recent pullback.
Revenue is expected to fall 57% next year. The company is still losing money. Recent earnings missed estimates twice. Workforce cuts show cost pressure.
The market expects about 57% revenue decline. Our fair value is $3.05. We see some optionality but risks remain high.
Breaks if: Fails to maintain funding through Q1 2027
Maintain sufficient cash and capital resources to fund company operations through the first quarter of 2027, including via milestone payments and cost reduction transactions.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on clinical development and the healthcare sector. The current thesis is cautious, reflecting mixed signals from management and recent performance.
The market appears to be pricing in a premium compared to peers, suggesting high expectations for MCRB's future performance. However, this premium may not be justified given the company's loss-making status and recent mixed results.
Management is focused on advancing clinical development and extending cash runway, which shows some positive momentum. However, the recent financial performance has been below the industry average, indicating potential challenges ahead.
The long-term thesis hinges on MCRB's ability to secure partnerships and funding for clinical trials, as well as the overall health of the healthcare sector. Key triggers include guidance updates and performance from sector peers.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats affecting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 4 quarters from 2025-Q3 through 2026-Q2. Cash was $15.6 million at 2026-Q2 end, with milestone payments from Nestlé totaling $25 million expected in 2026. Guidance extended from Q2 2026 to Q1 2027. Management is delivering on extending cash runway consistent with stated funding priority.
“Company expects to fund operations through the first quarter of 2027.”
“Based on current cash position and operating plans, expects to fund operations through the third quarter of 2026.”
“Company expects to fund operations through the third quarter of 2026.”
“Expect to fund operations through the second quarter of 2026.”
Breaks if: EPS loss worsens or fails to improve next year
Breaks if: Amendment fails or is reversed
Seres entered into an amendment to the Asset Purchase Agreement with Nestlé.
Breaks if: Revenue decline worse than -57% next year
Over the next 1 to 3 years, MCRB's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.